Sanofi-Aventis and Regeneron say that they have launched two Phase III trials for aflibercept--or VEGF Trap--with chemotherapy for lung and prostate cancer. The program has enormous potential if it succeeds in Phase III. The injectable therapy is designed to block the formation of abnormal blood vessels. VEGF triggers these new blood vessels to form in a process called angiogenesis. The blockbuster Avastin is currently the leading therapy in this field. Sanofi will provide an update on the program during its R&D day on September 17. The companies believe they can start seeking approval of the drug as early as next year.
- check out the release
Related Articles:
Regeneron, Genentech go head-to-head. Report
Regeneron wins rich pact for VEGF trap. Report